Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open Label Study to Assess the Efficacy and Safety of ABTL0812 in Combination With Paclitaxel and Carboplatin in Patients With Advanced Endometrial Cancer or Squamous NSCLC

NCT03366480 is registered in ClinicalTrials.gov with Ability Pharmaceuticals SL as lead sponsor.

NCT NCT03366480
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03366480 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open Label Study to Assess the Efficacy and Safety of ABTL0812 in Combination With Paclitaxel and Carboplatin in Patients With Advanced Endometrial Cancer or Squamous NSCLC
Lead sponsor
Ability Pharmaceuticals SL
Phase
Phase 1/2
Overall status
Completed
Start date
December 1, 2016
Completion date
November 15, 2020
Enrollment
103 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, squamous non-small cell lung cancer